Douglas Hunt
General Counsel chez PUMA BIOTECHNOLOGY, INC.
Fortune : 748 429 $ au 31/03/2024
Profil
Douglas Hunt is currently the Senior VP-Law, Regulatory & Medical Affairs at Puma Biotechnology, Inc. He previously worked as the Executive Director-Therapeutic Area at Amgen, Inc. from 2000 to 2008.
From 2008 to 2015, he was the Vice President-Global Regulatory Affairs at Baxter Healthcare Corp.
He then served as the VP-Regulatory Affairs & Quality Assurance at ArmaGen, Inc. from 2015 to 2017.
Mr. Hunt obtained his undergraduate degree from the University of Portsmouth.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
PUMA BIOTECHNOLOGY, INC.
0,29% | 12/02/2024 | 141 213 ( 0,29% ) | 748 429 $ | 31/03/2024 |
Postes actifs de Douglas Hunt
Sociétés | Poste | Début |
---|---|---|
PUMA BIOTECHNOLOGY, INC. | General Counsel | 01/01/2018 |
Anciens postes connus de Douglas Hunt
Sociétés | Poste | Fin |
---|---|---|
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | General Counsel | 01/12/2017 |
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | General Counsel | 01/01/2015 |
AMGEN INC. | Corporate Officer/Principal | 01/07/2008 |
Formation de Douglas Hunt
University of Portsmouth | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
AMGEN INC. | Health Technology |
PUMA BIOTECHNOLOGY, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Health Technology |
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Health Services |